Overview

Define Therapeutics Inc. discovers and develops innovative therapeutics for tough-to-treat prostate cancers such as castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC). Our novel strategy to modulate 2 or 3 key PARP-targets involved in the above pathogenesis with a single small-molecule is superior to the existing drugs. Using this approach, we plan to develop an orally-available small-molecule intended primarily for CRPC and NEPC in the clinic, but can also be further explored for other cancer indications.